Science
Endeavor
to Treat Severe Health Conditions
Author, A. A., Author B. B., & Author, C. C. (Year).
Title of Journal, Volume(Issue), pages–pages. https://doi.org/XXXXXXXXXXX
© 2023 – Endeavor Biomedicines | Privacy Notice | Terms of Use
Our Targeted Therapy Approach
Patients benefit from targeted treatments that focus on the drivers of disease. Our programs encompass novel strategies that, by specifically targeting the drivers of the disease, have the potential to offer more effective treatment options.
Idiopathic Pulmonary Fibrosis (IPF)
Hedgehog signaling is a driver of IPF: a progressive, irreversible, and fatal disease that causes tissue remodeling and scarring of the lungs.
Hedgehog Signaling Inhibition
Myofibroblasts are repair cells generated by the Hedgehog pathway— they become dysregulated in IPF, relentlessly remodeling lung tissue, forming fibrotic scar tissue, and contracting the lung. With approximately 132,000 people affected by IPF in the U.S. alone, there is a significant unmet need in this patient community, with people only surviving two to three years after initial diagnosis.
We are currently investigating ENV-101 in patients with IPF. For more information on this program, please visit our Pipeline page.
Oncology
HER3 is a receptor selectively overexpressed on many tumor types making it a good target for tumor-selective delivery of therapeutics.
HER3 Antibody Drug Conjugate (ADC)
Human epidermal growth factor receptor 3 (HER3/ErbB3) is a tyrosine kinase receptor belonging to the HER/EGFR family. HER3 is over-expressed in several cancers, with broader tumor expression than HER2. HER3 is over-expressed in tumors that show resistance to drugs that target other HER receptors such as EGFR and HER2, providing the opportunity to help patients with limited treatment options.
Endeavor’s HER3-targeted ADC attacks tumors while minimizing damage to healthy tissues thereby improving efficacy while reducing side effects.
ENV-501 is currently in the preclinical stage for patients positive for HER3 tumor expression. For more information on this program, please visit our Pipeline page.